180 Life Sciences announces notice of allowance for U.S. patent

180 Life Sciences (ATNF) announced that the United States Patent and Trademark Office has issued an official Notice of Allowance for U.S. Patent Application No. 17/556,584, covering a novel method for preventing or reducing Post-Operative Cognitive Dysfunction. The newly allowed patent covers a method for reducing POCD – particularly POCD manifested as delirium – by administering an anti-Human tumor necrosis factor Alpha monoclonal antibody to the patient in a therapeutically effective amount commencing just before and during the surgical procedure.